CMV Infection: A Clinical Challenge in Biological Therapy? The Case of Asymptomatic Patients with Persistent Positive Immunoglobulin M Anti-CMV Treated with Secukinumab.
anti-TNF-α therapy
biological therapy
case report
cytomegalovirus
immune-mediated inflammatory diseases
psoriasis
Journal
Psoriasis (Auckland, N.Z.)
ISSN: 2230-326X
Titre abrégé: Psoriasis (Auckl)
Pays: New Zealand
ID NLM: 101709086
Informations de publication
Date de publication:
2020
2020
Historique:
received:
30
09
2020
accepted:
11
11
2020
entrez:
7
12
2020
pubmed:
8
12
2020
medline:
8
12
2020
Statut:
epublish
Résumé
The use of biological therapy is now common practice in the treatment of immune-mediated inflammatory diseases (IMID). Currently, there are no guidelines related to the management of cytomegalovirus (CMV) infections or reactivation during therapy with biological agents. Furthermore, there is a lack of guidance on the management of asymptomatic patients with persistent positive immunoglobulin (Ig)M anti-CMV after an extended period and who have to undergo therapy with biological agents. We report the case of a patient in this situation for whom treatment with biological drugs for psoriasis was indicated. A good clinical response was obtained with secukinumab and maintained during 6 months of follow-up. No infectious disease or reactivation of CMV infection occurred. We suggest some possible guidelines for the management of such cases.
Identifiants
pubmed: 33282718
doi: 10.2147/PTT.S284701
pii: 284701
pmc: PMC7711202
doi:
Types de publication
Case Reports
Langues
eng
Pagination
57-60Informations de copyright
© 2020 Gambardella et al.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest in this work.
Références
J Infect. 2002 Feb;44(2):78-83
pubmed: 12076065
Reumatismo. 2016 Dec 16;68(3):144-147
pubmed: 27981816
Med Microbiol Immunol. 2019 Aug;208(3-4):415-429
pubmed: 30923898
Acta Derm Venereol. 2008;88(5):523-4
pubmed: 18779901
Dermatology. 2009;218(1):84-5
pubmed: 19005243
J Eur Acad Dermatol Venereol. 2018 Sep;32(9):1507-1514
pubmed: 29444376
Infect Disord Drug Targets. 2011 Oct;11(5):466-74
pubmed: 21827433
Eur J Clin Microbiol Infect Dis. 2014 Aug;33(8):1365-9
pubmed: 24584693
Arch Dermatol. 2009 Aug;145(8):961-2
pubmed: 19687445
Int J Dermatol. 2016 Nov;55(11):e600-e602
pubmed: 27261186